Thomas Dubensky Biography and Net Worth

Dr. Dubensky was the founding CEO of Tempest, joining the Company in 2017. He brings significant expertise in the discovery, development and translation of novel small molecule-, biologic- and vector-based cancer therapies, having advanced several first-in-human drug candidates. Dr. Dubensky previously held roles leading discovery biology, development and clinical translation in cancer immunotherapy and infectious disease indications at multiple biotech companies, including Viagene, Chiron, Onyx, Cerus and Immune Design. He has an extensive publication and patent record. Dr. Dubensky received his BA in Bacteriology and Immunology from the University of California, Berkeley, his PhD at the University of Colorado Health Sciences Center, conducted his post-doctoral studies at Harvard Medical School in the Department of Pathology and received executive training at the University of California, San Diego, Executive Program for Scientists and Engineers.